Bispecific antibody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFRJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62023-09-216OAAI
Novel Fab-peptide-HLA-I fusion proteins for redirecting pre-existing anti-CMV T cell immunity to selective eliminate carcinoma cellsONCOIMMUNOLOGYIF6.32023-05-103OA
Cancer cells under immune attack acquire CD47-mediated adaptive immune resistance independent of the myeloid CD47-SIRPα axisONCOIMMUNOLOGYIF6.32021-11-205OA
Bispecific antibody CD73xEpCAM selectively inhibits the adenosine-mediated immunosuppressive activity of carcinoma-derived extracellular vesiclesCANCER LETTERSIF10.12021-11-0115OA
Bispecific antibody approach for EGFR-directed blockade of the CD47-SIRPα don't eat me immune checkpoint promotes neutrophil-mediated trogoptosis and enhances antigen cross-presentationONCOIMMUNOLOGYIF6.32020-09-2927OAAI
Bispecific Antibody Approach for Improved Melanoma-Selective PD-L1 Immune Checkpoint BlockadeJOURNAL OF INVESTIGATIVE DERMATOLOGYIF5.72019-11-0121OAAI
CD20-selective inhibition of CD47-SIRPα don't eat me signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumabONCOIMMUNOLOGYIF6.32017-10-3157OAAI